Amgen Inc vs. 4D Molecular Therapeutics, Inc. Common Stock
Amgen Inc and 4D Molecular Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AMGN | FDMT | |
|---|---|---|
| Market Cap | $220.28 billion | $745.24 million |
| Revenue (TTM) | — | $92.01 million |
| Net Income (TTM) | — | $-179,175,000 |
AMGN leads on 1 of 1 size & scale factors.
Valuation
| AMGN | FDMT | |
|---|---|---|
| Price / Book | — | 1.83 |
| Price / Sales | — | 8.10 |
AMGN and FDMT split the valuation factors evenly.
Profitability
| AMGN | FDMT | |
|---|---|---|
| Net Margin | — | -194.74% |
| Return on Equity | — | -43.95% |
AMGN and FDMT split the profitability factors evenly.
Dividend
| AMGN | FDMT | |
|---|---|---|
| Dividend Yield | 2.43% | — |
AMGN and FDMT split the dividend factors evenly.
Risk & Sentiment
| AMGN | FDMT | |
|---|---|---|
| Short Interest | 1.66% | 0.41% |
FDMT leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, FDMT overview, FDMT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.